Payment overview · 2025
General Payments
$37.15
2 reported records · 2 companies
Healthcare provider profile · identity verified
Pamela Thompson, DO
Allopathic & Osteopathic Physicians|Family Medicine · HOLT, MI · NPI 1740244169
Verified facts
What the public records show
CMS Open Payments records show Pamela Thompson, DO received $37.15 in general payments during 2025 across 2 reported records.
PFIZER INC. accounted for 53.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.76 | 53.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.39 | 46.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $37.15 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 78 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
50 | 42 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
78 | 77 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
47 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 391 | 98 |
| Atorvastatin Calcium | Atorvastatin Calcium | 390 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 223 | 62 |
| Lisinopril | Lisinopril | 203 | 60 |
| Losartan Potassium | Losartan Potassium | 202 | 55 |
| Omeprazole | Omeprazole | 164 | 46 |
| Metformin Hcl | Metformin Hcl | 159 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 153 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 128 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 111 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 108 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 100 | 49 |
| Gabapentin | Gabapentin | 99 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 97 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 95 | 26 |
| Ezetimibe | Ezetimibe | 79 | 20 |
| Simvastatin | Simvastatin | 79 | 24 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 78 | 77 |
| Jardiance | Empagliflozin | 70 | 21 |
| Sertraline Hcl | Sertraline Hcl | 68 | 17 |
| Allopurinol | Allopurinol | 64 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 26 |
| Carvedilol | Carvedilol | 62 | 18 |
| Prednisone | Prednisone | 62 | 49 |
| Meloxicam | Meloxicam | 59 | 25 |
| Montelukast Sodium | Montelukast Sodium | 59 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 18 |
| Potassium Chloride | Potassium Chloride | 52 | 15 |
| Trulicity | Dulaglutide | 52 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 50 | 42 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 49 | 49 |
| Eliquis | Apixaban | 47 | 11 |
| Atenolol | Atenolol | 43 | 13 |
| Donepezil Hcl | Donepezil Hcl | 41 | suppressed |
| Famotidine | Famotidine | 40 | 14 |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 38 | 26 |
| Mirtazapine | Mirtazapine | 37 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Furosemide | Furosemide | 34 | 11 |
| Rybelsus | Semaglutide | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | 16 |
| Candesartan Cilexetil | Candesartan Cilexetil | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 30 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 29 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Risperidone | Risperidone | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | 11 |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 25 | 13 |
| Cephalexin | Cephalexin | 23 | 17 |
| Nystatin | Nystatin | 23 | 16 |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Calcitriol | Calcitriol | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 18 |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 17 |
| Clonazepam | Clonazepam | 19 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 19 | 12 |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 17 |
| Prolia | Denosumab | 17 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 15 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $37.15 · 2 records | PFIZER INC. | ABRYSVO, COMIRNATY, PREVNAR 20, TRELEGY ELLIPTA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error